{"id":"https://openalex.org/W1114352","doi":null,"title":"Strategies for preclinical immunogenicity assessment of protein therapeutics.","display_name":"Strategies for preclinical immunogenicity assessment of protein therapeutics.","publication_year":2009,"publication_date":"2009-03-01","ids":{"openalex":"https://openalex.org/W1114352","mag":"1114352","pmid":"https://pubmed.ncbi.nlm.nih.gov/19333897"},"language":"en","primary_location":{"id":"pmid:19333897","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/19333897","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"IDrugs : the investigational drugs journal","raw_type":"Journal Article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5069115228","display_name":"Philippe Stas","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Philippe Stas","raw_affiliation_strings":["Algonomics NV, Technologiepark 4, B-9052 Gent, Belgium. philippe.stas@algonomics.com"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Algonomics NV, Technologiepark 4, B-9052 Gent, Belgium. philippe.stas@algonomics.com","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5013144378","display_name":"Ignace Lasters","orcid":"https://orcid.org/0000-0001-5786-2590","observed_orcids":["https://orcid.org/0000-0001-5786-2590"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ignace Lasters","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":1.9471,"has_fulltext":false,"cited_by_count":26,"citation_normalized_percentile":{"value":0.85192456,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"12","issue":"3","first_page":"169","last_page":"73"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.9872999787330627,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.9872999787330627,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.009100000374019146,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11124","display_name":"Protein purification and stability","score":0.0015999999595806003,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/immunogenicity-assessment","display_name":"immunogenicity assessment","score":0.8579999804496765},{"id":"https://openalex.org/keywords/therapeutic-proteins","display_name":"therapeutic proteins","score":0.9850000143051147},{"id":"https://openalex.org/keywords/biological-therapy","display_name":"biologic therapy","score":0.9120000004768372},{"id":"https://openalex.org/keywords/antidrug-antibodies","display_name":"antidrug antibodies","score":0.9399999976158142},{"id":"https://openalex.org/keywords/risk-assessment","display_name":"risk assessment","score":0.7170000076293945},{"id":"https://openalex.org/keywords/drug-attrition","display_name":"drug attrition","score":0.652999997138977}],"concepts":[{"id":"https://openalex.org/C2780868878","wikidata":"https://www.wikidata.org/wiki/Q1660197","display_name":"Immunogenicity","level":3,"score":0.9762663841247559},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6483573913574219},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.596796452999115},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.42132091522216797},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.3377647399902344},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.334870845079422},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.2512441873550415},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.2365184724330902},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.17943042516708374}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000906","descriptor_name":"Antibodies","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":true},{"descriptor_ui":"D000906","descriptor_name":"Antibodies","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D000917","descriptor_name":"Antibody Formation","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D004353","descriptor_name":"Drug Evaluation, Preclinical","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011994","descriptor_name":"Recombinant Proteins","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D011994","descriptor_name":"Recombinant Proteins","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D011994","descriptor_name":"Recombinant Proteins","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D013601","descriptor_name":"T-Lymphocytes","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D013601","descriptor_name":"T-Lymphocytes","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D015195","descriptor_name":"Drug Design","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018570","descriptor_name":"Risk Assessment","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":1,"locations":[{"id":"pmid:19333897","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/19333897","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"IDrugs : the investigational drugs journal","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9922999739646912}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2952938091","https://openalex.org/W4378839962","https://openalex.org/W2092720388","https://openalex.org/W2054616299","https://openalex.org/W1991529485","https://openalex.org/W1989451953","https://openalex.org/W4411123425","https://openalex.org/W4406751833","https://openalex.org/W2065711632","https://openalex.org/W3152173043"],"abstract_inverted_index":{"The":[0],"immunogenicity":[1,37,97,124,134,163],"assessment":[2,31,70,121,164],"of":[3,19,32,52,54,64,84,91,122,132,145,165],"protein":[4,166],"therapeutics":[5],"has":[6,40],"received":[7],"significant":[8],"attention,":[9],"both":[10],"from":[11],"regulatory":[12],"bodies":[13],"and":[14,24,113,139,157],"industry.":[15],"With":[16],"the":[17,25,29,36,50,62,81,89,92,102,120,130,142,153,161],"advent":[18],"several":[20],"industry":[21],"white":[22],"papers":[23],"EMEA":[26],"guidance":[27],"on":[28],"clinical":[30,137,148],"antidrug":[33],"antibodies":[34],"(ADAs),":[35],"screening":[38],"framework":[39],"become":[41],"better":[42],"defined.":[43],"Immunogenicity":[44],"in":[45,106,125,147],"many":[46],"cases":[47],"leads":[48],"to":[49,61,79,109,136,160],"loss":[51],"efficacy":[53],"a":[55,110,126],"drug,":[56],"but":[57],"can":[58],"also":[59],"lead":[60],"production":[63],"severe":[65],"adverse":[66,93],"effects.":[67],"A":[68],"risk":[69],"should":[71],"be":[72],"conducted":[73],"for":[74],"every":[75],"biotherapeutic":[76],"under":[77],"development":[78],"address":[80],"incidence":[82],"rate":[83,144],"immunogenicity,":[85],"as":[86,88],"well":[87],"severity":[90],"effects":[94],"caused.":[95],"Typically,":[96],"is":[98],"characterized":[99],"by":[100],"measuring":[101],"ADAs":[103],"that":[104],"occur":[105],"individuals":[107],"exposed":[108],"drug.":[111],"Industry":[112],"academic":[114],"research":[115],"efforts":[116],"are":[117],"geared":[118],"toward":[119],"potential":[123],"preclinical":[127],"setting,":[128],"with":[129],"aim":[131],"predicting":[133],"prior":[135],"trials,":[138],"thereby":[140],"reducing":[141],"attrition":[143],"drugs":[146],"development.":[149],"This":[150],"article":[151],"addresses":[152],"current":[154],"status,":[155],"strategies":[156],"challenges":[158],"related":[159],"predictive":[162],"therapeutics.":[167]},"counts_by_year":[{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":1},{"year":2018,"cited_by_count":2},{"year":2016,"cited_by_count":1},{"year":2014,"cited_by_count":2},{"year":2013,"cited_by_count":4},{"year":2012,"cited_by_count":6}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}